- Home
- RVT vs DNLI Comparison
RVT vs DNLI Comparison
Compare RVT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- DNLI
- Stock Information
- Founded
- RVT 1986
- DNLI 2013
- Country
- RVT United States
- DNLI United States
- Employees
- RVT N/A
- DNLI N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVT Finance
- DNLI Health Care
- Exchange
- RVT Nasdaq
- DNLI Nasdaq
- Market Cap
- RVT 1.9B
- DNLI 1.8B
- IPO Year
- RVT N/A
- DNLI 2017
- Fundamental
- Price
- RVT $13.61
- DNLI $14.87
- Analyst Decision
- RVT
- DNLI Strong Buy
- Analyst Count
- RVT 0
- DNLI 15
- Target Price
- RVT N/A
- DNLI $38.00
- AVG Volume (30 Days)
- RVT 243.4K
- DNLI 1.8M
- Earning Date
- RVT 01-01-0001
- DNLI 05-06-2025
- Dividend Yield
- RVT 7.32%
- DNLI N/A
- EPS Growth
- RVT N/A
- DNLI N/A
- EPS
- RVT 2.95
- DNLI N/A
- Revenue
- RVT N/A
- DNLI N/A
- Revenue This Year
- RVT N/A
- DNLI N/A
- Revenue Next Year
- RVT N/A
- DNLI $372.05
- P/E Ratio
- RVT $4.98
- DNLI N/A
- Revenue Growth
- RVT N/A
- DNLI N/A
- 52 Week Low
- RVT $11.85
- DNLI $10.57
- 52 Week High
- RVT $14.93
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- RVT 47.39
- DNLI 55.64
- Support Level
- RVT $13.00
- DNLI $12.31
- Resistance Level
- RVT $13.50
- DNLI $13.63
- Average True Range (ATR)
- RVT 0.55
- DNLI 1.09
- MACD
- RVT 0.08
- DNLI 0.44
- Stochastic Oscillator
- RVT 73.76
- DNLI 85.66
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.